SCHEMBL8224879

SCHEMBL8224879

CN(C)C(=O)CN1C(=O)C2(CCN(C(=O)OC(C)(C)C)CC2)C1c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
GPR119 Q8TDV5 1/20 0.42
TACR1 P25103 1/20 0.41
USP30 Q70CQ3 2/20 0.41
KDM4E B2RXH2 1/20 0.41
PKM P14618 1/20 0.41
KDM1A O60341 1/20 0.41
NPC1L1 Q9UHC9 2/20 0.40
TRPV1 Q8NER1 3/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
ATM Q13315 1/20 0.40
BACE1 P56817 1/20 0.40
OPRD1 P41143 1/20 0.39
OPRK1 P41145 1/20 0.39
DTYMK P23919 1/20 0.39
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8224883 0.91 GPR119 (0.43) HDAC1HDAC6GPR119NPC1L1
SCHEMBL14263479 0.90 MEN1 (0.43) HDAC1HDAC6
SCHEMBL8227881 0.89 HDAC1 (0.55) HDAC1HDAC6GPR119KDM4EKDM1A
SCHEMBL8208288 0.86 HDAC1 (0.47) HDAC1HDAC6GPR119TACR1USP30
SCHEMBL14263460 0.85 GPR119 (0.44) HDAC1HDAC6GPR119USP30KDM1A
SCHEMBL8218924 0.83 HDAC1 (0.47) HDAC1HDAC6GPR119TACR1USP30
SCHEMBL8227850 0.81 HDAC1 (0.45) HDAC1HDAC6GPR119TACR1USP30
SCHEMBL8218899 0.80 GPR119 (0.48) HDAC1HDAC6GPR119USP30KDM4E
SCHEMBL8218912 0.80 HDAC1 (0.46) HDAC1HDAC6GPR119TACR1USP30
SCHEMBL8212694 0.78 TRPV1 (0.61) HDAC1HDAC6GPR119USP30NPC1L1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080076750-A1 Azetidinone Derivatives and Methods of Use Thereof SCHERING CORPORATION 2008-03-27 US disclosed
US-20080076750-A1 Azetidinone Derivatives and Methods of Use Thereof SCHERING CORPORATION 2008-03-27 US disclosed
WO-2008033460-A2 TREATING PAIN, DIABETES, AND LIPID METABOLISM DISORDERS SCHERING CORPORATION (US) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076750-A1 Azetidinone Derivatives and Methods of Use Thereof LIPC, CES1, ZDHHC20 HDAC1 937/4885HDAC6 2818/4885GPR119 81/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.